Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신상훈 | - |
dc.date.accessioned | 2024-05-20T16:31:08Z | - |
dc.date.available | 2024-05-20T16:31:08Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 0009-7322 | - |
dc.identifier.other | OAK-34906 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/268434 | - |
dc.description.abstract | BACKGROUND: Stopping aspirin within 1 month after implantation of a drug-eluting stent for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome. The aim of this study was to investigate whether ticagrelor monotherapy after <1 month of dual antiplatelet therapy (DAPT) is noninferior to 12 months of ticagrelor-based DAPT for adverse cardiovascular and bleeding events in patients with acute coronary syndrome. METHODS: In this randomized, open-label, noninferiority trial, 2850 patients with acute coronary syndrome who underwent drug-eluting stent implantation at 24 centers in South Korea were randomly assigned (1:1) to receive either ticagrelor monotherapy (90 mg twice daily) after <1 month of DAPT (n=1426) or 12 months of ticagrelor-based DAPT (n=1424) between April 24, 2019, and May 31, 2022. The primary end point was the net clinical benefit as a composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, stroke, and major bleeding at 1 year after the index procedure in the intention-to-treat population. Key secondary end points were the individual components of the primary end point. RESULTS: Among 2850 patients who were randomized (mean age, 61 years; 40% ST-segment-elevation myocardial infarction), 2823 (99.0%) completed the trial. Aspirin was discontinued at a median of 16 days (interquartile range, 12-25 days) in the group receiving ticagrelor monotherapy after <1 month of DAPT. The primary end point occurred in 40 patients (2.8%) in the group receiving ticagrelor monotherapy after <1-month DAPT, and in 73 patients (5.2%) in the ticagrelor-based 12-month DAPT group (hazard ratio, 0.54 [95% CI, 0.37-0.80]; P<0.001 for noninferiority; P=0.002 for superiority). This finding was consistent in the per-protocol population as a sensitivity analysis. The occurrence of major bleeding was significantly lower in the ticagrelor monotherapy after <1-month DAPT group compared with the 12-month DAPT group (1.2% versus 3.4%; hazard ratio, 0.35 [95% CI, 0.20-0.61]; P<0.001). CONCLUSIONS: This study provides evidence that stopping aspirin within 1 month for ticagrelor monotherapy is both noninferior and superior to 12-month DAPT for the 1-year composite outcome of death, myocardial infarction, stent thrombosis, stroke, and major bleeding, primarily because of a significant reduction in major bleeding, among patients with acute coronary syndrome receiving drug-eluting stent implantation. Low event rates, which may suggest enrollment of relatively non-high-risk patients, should be considered in interpreting the trial. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03797651. © 2024 Lippincott Williams and Wilkins. All rights reserved. | - |
dc.language | English | - |
dc.publisher | Lippincott Williams and Wilkins | - |
dc.subject | acute coronary syndrome | - |
dc.subject | antiplatelet agent | - |
dc.subject | aspirin | - |
dc.subject | drug-eluting stents | - |
dc.title | Stopping Aspirin Within 1 Month after Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial | - |
dc.type | Article | - |
dc.relation.issue | 8 | - |
dc.relation.volume | 149 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 562 | - |
dc.relation.lastpage | 573 | - |
dc.relation.journaltitle | Circulation | - |
dc.identifier.doi | 10.1161/CIRCULATIONAHA.123.066943 | - |
dc.identifier.wosid | WOS:001167123800004 | - |
dc.identifier.scopusid | 2-s2.0-85179695121 | - |
dc.author.google | Hong | - |
dc.author.google | Sung-Jin | - |
dc.author.google | Lee | - |
dc.author.google | Seung-Jun | - |
dc.author.google | Suh | - |
dc.author.google | Yongsung | - |
dc.author.google | Yun | - |
dc.author.google | Kang | - |
dc.author.google | Tae Soo | - |
dc.author.google | Shin | - |
dc.author.google | Sanghoon | - |
dc.author.google | Kwon | - |
dc.author.google | Sung Woo | - |
dc.author.google | Jun-Won | - |
dc.author.google | Cho | - |
dc.author.google | Deok-Kyu | - |
dc.author.google | Park | - |
dc.author.google | Jong-Kwan | - |
dc.author.google | Bae | - |
dc.author.google | Jang-Whan | - |
dc.author.google | Woong Cheol | - |
dc.author.google | Kim | - |
dc.author.google | Seunghwan | - |
dc.author.google | Yong-Joon | - |
dc.author.google | Ahn | - |
dc.author.google | Chul-Min | - |
dc.author.google | Jung-Sun | - |
dc.author.google | Kyeong Ho | - |
dc.author.google | Byeong-Keuk | - |
dc.author.google | Ko | - |
dc.author.google | Young-Guk | - |
dc.author.google | Choi | - |
dc.author.google | Donghoon | - |
dc.author.google | Jang | - |
dc.author.google | Yangsoo | - |
dc.author.google | Myeong-Ki | - |
dc.contributor.scopusid | 신상훈(7403646689;27868133100) | - |
dc.date.modifydate | 20240520121916 | - |